Advancing research in myeloproliferative Neoplasms

MPN Research Foundation funds and advances original research in pursuit of new treatments — and ultimately a cure — for essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), the blood cancers known as myeloproliferative neoplasms (MPNs). Founded in 1999 as the first organization dedicated to MPNs, the Foundation remains the global leader in accelerating MPN research. Its collaborative, patient-centered approach brings experts together, elevates the patient voice, and propels scientific progress in these complex diseases.

Our work focuses on accelerating MPN research in three critical ways.

  • We invest in innovative, early-stage MPN Research.

    Expert‑reviewed science advances understanding of myeloproliferative neoplasms and informs future therapeutic progress.

  • We elevate patient insights in research and drug development.

    Patient-reported data and lived experience help shape research priorities and trial design.

  • We convene experts across the MPN ecosystem.

    Bringing researchers and clinicians, patients and caregivers, and biopharmaceutical professionals together accelerates scientific progress.

Our impact across the global MPN research ecosystem

$20.2M

Total donated dollars
invested in research


99

Researchers supported


10

Countries with
supported research


106

Projects funded


Together, individual drops of data can make an ocean of change.

Understanding MPNs is essential to advancing research.

Our research spans essential thrombocythemia (ET), polycythemia vera (PV), and
myelofibrosis (MF), which together are known as myeloproliferative neoplasms.

Be part of the solution

There are many ways to contribute to advancing MPN research, depending on how you want to engage.

Researcher & Clinicians

Advance discovery by pursuing early‑stage research, collaborating with peers, and contributing to field‑wide scientific alignment.

Patients & Caregivers

Share your experience, stay
informed on research progress,
and help ensure patient insights
shape the future of MPN science.

Biopharmaceutical Industry

Engage through neutral collaboration that integrates patient insights and academic expertise to move MPN science forward responsibly.

Invest in MPN research

Join the community

Be the first to know about the latest news and advancements for ET, PV, and MF. Sign up to receive our newsletters and alerts.

Recent news